Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Merestinib (Primary) ; Ramucirumab (Primary) ; Cisplatin; Gemcitabine
- Indications Biliary cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 22 Dec 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Mar 2018.
- 14 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Jun 2017 Planned End Date changed from 1 Jun 2018 to 1 May 2020.